

Country General Information (WHO, 2013)

Total population:	77,447,000	Age group <15/>14 years, %:	24% / 76%
Gender (% F/M):	49.7% / 50.3%	Life expectancy at birth in years (F/M):	76 / 72
GDP (PPP int \$):	15 600	Number of 3rd sub-national administrative level divisions, name:	999, District
Income status:	Upper middle		





Epidemiology

	VL	ACL	ZCL	MCL
Endemicity status:	Endemic	Endemic	Endemic	Non endemic
Number of new cases (incidence):	52	2224	18722	N/A
Number of relapse cases:	2	67	135	N/A
Total number of cases:	54	2291	18857	N/A
Imported cases (n, %):	28 (52%)	363 (16%)	4761 (25%)	No data
Gender distribution (% F):	39%	50%	41%	N/A
Age group distribution (% <5/5-14/>14):	(80 / 11 / 9)	(8 / 23 / 69)	(1 / 20 / 66)	N/A
Incidence rate (cases/10 000 population in endemic areas ³):	0.03	2.31	7.58	N/A
Number of endemic 3rd sub-national administrative level divisions (n):	30	160	842	N/A
Population at risk ¹ (% n/total):	27% (20592663/75156975)	13% (9644311 / 75156975)	32% (24706766 / 75156975)	N/A
Was there any outbreak?	No	No	Yes	N/A
Number of new ² foci:	No data	No data	No data	N/A

N/A = not applicable VL = visceral leishmaniasis ACL = anthroponotic cutaneous leishmaniasis ZCL = zoonotic cutaneous leishmaniasis MCL = mucocutaneous leishmaniasis

Monthly distribution of new cases January-December

2014	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	3	9	6	3	3	3	5	10	1	4	3	4
ACL	204	205	150	216	219	243	194	162	177	135	154	165
ZCL	2718	2183	1402	395	403	280	337	676	1488	2491	3065	3284

Number of new CL cases reported by month in 2013 and 2014

Number of new (primary) VL cases reported by month in 2013 and 2014

Incidence rate/10 000 population and number of new CL (left) and new (primary) VL (right) cases from 1998 to 2014


¹ The denominator is the population at risk as defined in Shirzadi et al, 2015.

* No data available


² Defined as "Number of people living in 3rd sub-national administrative level endemic areas", as for the Shirzadi et al, 2015

³ For this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever

³ Incidence rate at the national level

Distribution of new CL (left) and new (primary) VL (right) cases

Incidence of CL in Islamic republic of Iran in 2014 at province level, per 10 000 population



No data reported at subnational level for VL

Incidence of ACL in the two most endemic counties of the Islamic republic of Iran, per 10 000 inhabitants



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
Map production: WHO/HTM/NTD/IDM

Control and surveillance

Year Leishmaniasis National Control Programme (LNCP) was established:	2007	Year latest national guidelines were published:	2007
Type of surveillance:	Integrated	Is leishmaniasis notifiable (mandatory reporting)?	Yes
Is there a vector control programme?	Yes	Is there a reservoir host control programme?	Yes
Type of insecticide used for IRS:	Deltamethrin	Number of leishmaniasis health facilities:	1002

Diagnosis

	VL	ACL	ZCL	MCL
Number of people screened actively for:	0	0	0	N/A
Number of people screened passively for:	54	2291	18857	N/A
VL cases diagnosed by RDT* (%, RDT+/total VL cases):	40% (21 / 54)	N/A	N/A	N/A
Proportion of positive RDT* (%, RDT+/total RDT):	100% (21 / 21)	N/A	N/A	N/A
Cases diagnosed by direct exam (parasitology) (% , # slides +/total cases):	22% (12 / 54)	98% (2245 / 2291)	74% (14012 / 18857)	N/A
Proportion of positive slides (%, slides +/total slides):	80% (12 / 15)	100% (2245 / 2250)	99% (14012 / 14219)	N/A
Cases diagnosed clinically (%, nb clinical cases/ total cases):	100% (54 / 54)	2% (41 / 2291)	25% (4638 / 18857)	N/A
Percentage of cases with HIV-VL coinfection:	0% (0 / 54)	N/A	N/A	N/A

* These indicators apply only for primary VL cases VL = visceral leishmaniasis ACL = anthroponotic cutaneous leishmaniasis ZCL = zoonotic cutaneous leishmaniasis
N/A = not applicable RDT = rapid diagnostic test HIV = human immunodeficiency virus MCL = mucocutaneous leishmaniasis

Treatment and medicines

Is treatment provided free of charge in the public sector?	Yes
Antileishmanial medicines included in the national List of Essentials Medicines:	Meglumine antimoniate , miltefosine

TREATMENT OUTCOME	VL	
Proportion of relapse cases: ⁴	4%	(2 / 54)
Initial cure rate:	80%	(43 / 54)
Failure ⁵ rate:	0%	(0 / 54)
Case-fatality rate:	0%	(0 / 54)

⁴ A relapse case in this country is defined as:

For CL: Case that after having received complete local or systemic treatment is considered cured and then the disease reappears in the same area.

For VL: Case with symptoms reappearing 6 months after completing treatment.

⁵ A failure case in this country is defined as:

Case with no clinical cure or reappearance of symptoms within 2 weeks after completing treatment.

Data source: Ministry of Health, Iran (Islamic Republic of)
© WHO 2014. All rights reserved.